| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WHITEHOUSE STATION, N.J.—Ending a 22-year-old partnership, Merck& Co., known outside the United States and Canada as MSD,announced this week that the company has sold its 50 percent interest in theJohnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture(JJMCP) to Johnson & Johnson Inc. Following the transaction, J&J will own the venture'sassets, which include the exclusive rights to market over-the-counter Pepcid,Mylanta, Mylicon and other local OTC brands where they are currentlysold in the United States and Canada. The partnership assets include amanufacturing facility in Lancaster, Pa.
 
The venture betweenMerck and J&J was formed in 1989 to develop, manufacture, market anddistribute certain OTC consumer products in theUnited States and Canada.Merck decided to sell its interest in the joint venture "toenable the company to fully focus on building the long-term growthprospects of the wholly-owned consumer products division that had beenpart of Schering-Plough Inc. prior to the 2009 merger."
 
Under theagreement, Merck will receive a one-time payment of $175 million.Merck's rights to the Pepcid brand outside the U.S. and Canada are notaffected by this transaction. Termination of the JJMCP venture, which will be renamed McNeil Consumer Pharmaceuticals Co., reportedly will alsogive Merck greater freedom to operate in the OTC consumer sector,"allowing Merck to fully exploit its pipeline of Rx-to-OTC switches aswell as actively pursue OTC licensing activities in the U.S. and Canada," according to a company news release.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue